Nexobrid (Concentrate Of Proteolytic Enzymes Enriched In Bromelain)

The bromelain enzymes break down protein structures in dead tissue by hydrolyzing peptide bonds. This selective proteolysis dissolves eschar while sparing viable skin, allowing clinicians to clear the wound bed without mechanical excision.

The prescribed amount of Nexobrid is determined by the treating physician based on burn depth, surface area, and patient factors. The clinician decides the volume of gel to apply and the duration of treatment for each individual case.

The safety of Nexobrid in pregnancy or while breastfeeding has not been established. Because systemic absorption is minimal, it is generally avoided unless the potential benefit outweighs any possible risk, and only under medical supervision.

To request Nexobrid, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with surgical excision, Nexobrid offers a non‑invasive, selective enzymatic approach that can reduce operative time and preserve healthy tissue. Unlike some chemical debriders, it is specifically formulated for deep partial‑thickness burns and has a well‑characterised safety profile when used as directed.

Nexobrid should be stored below 25 °C in its original packaging, protected from moisture and direct light. The gel must be kept sealed until use and any opened container should be used within the timeframe specified by the manufacturer.

After cleaning the burn area, the prescribed amount of Nexobrid gel is spread evenly over the necrotic tissue. The wound is then covered with a suitable dressing for the duration recommended by the clinician, after which the debrided tissue is removed and the wound reassessed.

The most serious risks include severe allergic reactions such as anaphylaxis, unintended deep tissue necrosis beyond the target area, and secondary infection of the treated wound. Prompt medical attention is required if any of these events occur.

Nexobrid should not be used in patients with known hypersensitivity to bromelain or pineapple-derived products, on healthy skin, or on burns that are not classified as deep partial‑thickness. It is also contraindicated in individuals receiving conflicting topical debriding agents without medical guidance.